The monetary evaluation for QALY gain is necessary and important information for decision making about medical or public health policies. Even though there is one empirical research about it, it used direct methods to estimate its WTP and thus it has a lot of problems. This paper aims to study the same purpose but by using Conjoint analysis. METHODS: A survey was conducted in the 2005 fiscal year and questionnaires were distributed and collected from 773 households, of which the return rate was 88%. The subjects are 1297 adults over age 20. In addition to socio-economic characteristics, in this survey respondents were asked a hypothetical question for Conjoint analysis; whether they would agree to the medical care under the hypothetical situation in regards to cost, duration, the number of patients, and health status. We also performed sensitive analysis in regards to explanatory variables in the estimation equation, discount factors, and QOL evaluation for health status. RESULTS: In all equation, the estimated coefficients of total cost are significantly negative and those of QALY gain are significantly positive. CONCLUSIONS: WTP per QALY gain is estimated to be 635 to 675 thousand Japanese yen or 5773 to 6136 US$ assuming 1US$ = 110 Japanese yen. Income does not affect WTP per QALY significantly. Side effects include drug-induced symptoms which are predominantly communicated by patient self-report. This year, the FDA produced draft recommendations for the validation of patient-reported outcomes, for use in medical product development studies. The growing interest in side effects in medical research and the regulatory environment, presents an urgent need for properly developed patient-reported outcome measures of drug side effects. These measures must be valid, reliable and reproducible. METHODS: To assess the psychometric properties of patient-reported side effect symptom scales, and to describe and evaluate the methodologies used to create them. RESULTS: Fifteen existing scales were identified and reviewed. There was wide variation in the extent to which the psychometric properties of the instruments had been reported or tested. There were disagreements amongst scale developers concerning the appropriateness of use of certain reliability tests which are usually routinely undertaken during questionnaire development. The responsiveness testing of side effect scales may be problematic to carry out and testing was limited amongst reviewed scales. Since any symptom of a drug intervention may be associated with everyday health problems, the disease being treated, the drug treatment or a combination of these causes, measuring drug-related side effects is complicated. This complexity impacts upon all aspects of the psychometric testing of patient-reported scales, creating unique challenges for their developers, who must create tools which appropriately discriminate between side effects and symptoms. CONCLUSION: The potential usefulness of patient-reported side effect scales is broad: from research outcome to clinical monitoring. However, a consensus must be reached on suitable methods for the development of such scales.
PMC14 MEASURING PATIENT-REPORTED SIDE EFFECTS OF DRUGS: ITS IMPORTANCE AND METHODOLOGICAL CHALLENGES
University of Groningen, Groningen, The Netherlands, 2 ALTANA Pharma AG, Konstanz, Germany, 3 University of Aberdeen, Aberdeen, Scotland, UK INTRODUCTION: Side effects include drug-induced symptoms which are predominantly communicated by patient self-report. This year, the FDA produced draft recommendations for the validation of patient-reported outcomes, for use in medical product development studies. The growing interest in side effects in medical research and the regulatory environment, presents an urgent need for properly developed patient-reported outcome measures of drug side effects. These measures must be valid, reliable and reproducible. METHODS: To assess the psychometric properties of patient-reported side effect symptom scales, and to describe and evaluate the methodologies used to create them. RESULTS: Fifteen existing scales were identified and reviewed. There was wide variation in the extent to which the psychometric properties of the instruments had been reported or tested. There were disagreements amongst scale developers concerning the appropriateness of use of certain reliability tests which are usually routinely undertaken during questionnaire development. The responsiveness testing of side effect scales may be problematic to carry out and testing was limited amongst reviewed scales. Since any symptom of a drug intervention may be associated with everyday health problems, the disease being treated, the drug treatment or a combination of these causes, measuring drug-related side effects is complicated. This complexity impacts upon all aspects of the psychometric testing of patient-reported scales, creating unique challenges for their developers, who must create tools which appropriately discriminate between side effects and symptoms. CONCLUSION: The potential usefulness of patient-reported side effect scales is broad: from research outcome to clinical monitoring. However, a consensus must be reached on suitable methods for the development of such scales. The Resource Group, Pickton, TX, USA OBJECTIVE: Drug delivery delays are a recurring management issue that causes costly disruptions in hospital work flow. This project examines reported delivery time from the hospital pharmacy to the hospital outpatient department where the drug or biologic is to be administered. The focus is upon drugs that are expensive, that require reconstitution and that are often prepared only after notification that the patient has arrived. METHODS: Data were collected from 54 hospital pharmacies, including onsite observations of pharmacy activities and related infusion therapy in hospital outpatient departments (HOPDs) in 19 states (n = 24) and from a telephone survey of other hospital DOPs located in 17 states (n = 30). Survey instruments were pretested. The sampling frame was a broad-based convenience sample. Facility-specific data were entered into a database and matched with facility demographics retrieved from a government database. Unit of analysis was the pharmacy. Statistical analysis yielded descriptive statistics. RESULTS: The on-site observers determined that those HOPDs that delivered the drug to be infused from the main pharmacy (54.2%) incurred a statistically significant mean wait time of 37.5 minutes. The remaining facilities (45.8%) incurred negligible wait times because the drug was reconstituted adjacent to or on site. Respondents to the telephone survey reported a 17.4 minute mean delivery time regardless of pharmacy location. Tasks contributing to wait time included mixing, dispensing and transporting. Delivery was made by pharmacy technicians in 80.8% of facilities and by specially designated transport staff provided by the pharmacy department in 19.2% of the facilities surveyed. CONCLU-SIONS: Hospital pharmacy decision-makers need actionable information in order to better manage drug delivery delays that disrupt work flow and decrease patient satisfaction. This study provides detailed activity analysis information and process mapping that can be readily applied to facility-specific relevant pharmacy staffing and management decisions.
PMC16 PROPOSED CHANGES TO PHYSICIAN FEE SCHEDULE: 2007 PRACTICE EXPENSE CONCEPTUAL METHODOLOGY
Pierce CA 1 , Baker JJ 2 1 The Resource Group, Richfield, OH, USA, 2 The Resource Group, Pickton, TX, USA OBJECTIVE: The Centers for Medicare and Medicaid Services (CMS) has proposed methodological changes to the computation of 2007 physician fee schedule practice expense. The proposed changes appear to reduce payment for drug administration. This study explores the methodological design of these proposed changes and seeks to identify primary drivers within the methodology. METHODS: Various methods of computing practice expense for 2007 as proposed by CMS were collected and categorized in a methods database format. Data sources and formulas for each proposed method were identified. Current computation methods in effect for calendar year 2006 were then identified and divided into segments for purposes of comparison. Proposed methods were compared against each other and against the payment structure currently in effect. This comparative analysis highlighted methodological drivers. RESULTS: CMS initially proposed four methods of computing practice expense in 2007. Three potential data sources were identified: the Socioeconomic Monitoring System (SMS); the Medicare Economic Index (MEI); and the Clinical Practice Expert Panel (CPEP). The four proposed methods utilized various combinations of these sources. Each proposed formula was based upon a series of allocations that resulted in different percentages assigned to different subcomponents of the relevant methodology. Comparative analysis revealed significant differentials. Payments for drug administration in the physician's office would be reduced by all four proposed methods. Two primary methodological drivers were identified: allocation between direct expense and indirect expense within each formula and the volume-based allocation method, whereby specialty impacts are recognized but are then weighted by specialty-specific volume. CONCLUSIONS: Many physician fee schedule payment rates in 2007, including drug administration procedures, may be significantly impacted by proposed changes to the practice expense computation methods. It is vital for service provider decision-makers to monitor and understand relevant CMS proposals. Otherwise, if significant underpayment occurs in 2007, patient access may be negatively affected.
PMC17 MONITORING OF PHARMACEUTICAL COST OF REIMBURSED MEDICINES BY COMBINING OFFICIAL PHARMACY INVOICE DATA WITH COMMERCIAL IMS SALES DATA
Van Wilder P, Arickx F,Van Haeren E, Bormans V RIZIV-INAMI, Brussels, Belgium OBJECTIVES: In Belgium reimbursement submissions must contain scientific and financial elements. The financial part relies on budget impact (BI) estimates from the payer's perspective for the next 3 years. Real cost monitoring is difficult because official cost data become available with a substantial delay while commercial IMS data measure total sales. Our aim was to develop a method to monitor pharmaceutical expenses in Belgium and compare the outcome with the expected costs of the BI-estimation: a method combining both data sources allowed to monitor in a timely manner only the reimbursed pharmaceutical cost.
METHODS:
The method was applied on the class of cholesterol lowering drugs representing 9% of ambulatory expenses. BI-estimations were provided in the applicant's dossier. Monthly IMSsales data (=S, IMS-Health) and official cost data (=C, Riziv) were extracted from the respective databases. RESULTS: All correlations between historical monthly product data from both sources yielded an R 2 > 0.75 which was considered as a cut-off to apply the method (minimal R 2 = 0.8164). Expected reimbursement pharmaceutical cost was calculated as: Expected C = S/k where k is the average monthly ratio of S to C during a common 12 month period. The expected C calculation extends real C data by 6 months. Quality control of the method was assessed by comparing the expected C and real C yielding a mean monthly error lower than 5% with a 3 month cumulated error of less than 2%. BI-estimates were inferior to expected and real C. CONCLU-SIONS: A method was developed to predict 3rd payer's pharmaceutical cost combining recent commercial sales data and official but less recent cost data ensuring reliable application of this method for control of estimates of BI.
PMC18 USING DISTANCE LEARNING TO UNDERSTAND DISCRETE EVENT SIMULATION
Hunting B, Moller J, Caro JJ Caro Research Institute, Concord, MA, USA OBJECTIVES: The many benefits of pharmacoeconomic modeling using Discrete Event Simulation (DES) have increased interest in this methodology. A paucity of courses applied to medical problems however, combined with busy schedules prohibit many professionals from familiarizing themselves with the technique. Meeting these needs requires training that can be conducted over the internet. METHODS: A distance learning course was developed to provide a basic understanding of DES. Using Flash technology, an internationally accepted web standard, learning materials were organized into discrete Lessons of online information. Each Lesson is a collection of video, narration, and text explaining a particular aspect of DES such as its theoretical underpinnings, examples of implemented DES solutions, and indepth explanations of model logic. While Lessons are grouped together in Modules which address a specific range of concepts, each Lesson can also stand on its own. This allows the student to approach the course at their own pace and navigate the curriculum according to personal interest and experience level. This granular organizational method also enables individual lessons to serve as reference materials. RESULTS: The interactive course allows students to manipulate flowchart exercises, self-certify their knowledge through instantly processed quizzes, and contact course administrators with questions. Accessing the course requires only a broadband internet connection, a standard web browser and the Flash player plug-in. CONCLUSIONS: When considering the time and expense of attending geographically dispersed educational seminars, as well as the difficulties associated with participating in large group lectures, the advantages of a tailored, interactive online course become clear. Combining an interactive multimedia presentation approach with a deep curriculum and an at-your-own-pace learning process, the online DES course provides students with an effective and convenient solution for learning about DES in the pharmacoeconomic field. Gastrointestinal stromal tumors (GIST) is the relatively new term for gastric and intestinal smooth muscle tumors arising from mesenchymal or connective tissue. Knowledge of the epidemiologic, health-related quality of life (HRQL), and economic burden of GIST is important from payer, provider, and patient perspectives and may help guide coverage and treatment decisions for treatments recently available. METHODS: PubMed and six scientific meeting databases were searched for studies of GIST and epidemiology, HRQL, or economics. Relevant publications were assessed as to whether they provided original empirical research. RESULTS: Eleven publications met the review criteria: eight provided data on GIST incidence, and one each on prevalence, HRQL, and cost. Incident cases were identified by medical record review or through extant databases with prospective confirmation by immunohistochemical staining in six studies. The annualized incidence of GIST (cases per million) was: United States (U.S.) (6.8), Iceland (11.0), The Netherlands (12.7), Italy (13), Taiwan (13.7) Sweden (14.5), , and France (20.4). Prevalence was estimated at 129 cases per million in Sweden. On the Functional Illness of Chronic Therapy-fatigue instrument, GIST patients scored 40.0 compared to 23.9, 37.6, and 43.6 in anemic cancer, non-anemic
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